JP2020504711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504711A5 JP2020504711A5 JP2019526486A JP2019526486A JP2020504711A5 JP 2020504711 A5 JP2020504711 A5 JP 2020504711A5 JP 2019526486 A JP2019526486 A JP 2019526486A JP 2019526486 A JP2019526486 A JP 2019526486A JP 2020504711 A5 JP2020504711 A5 JP 2020504711A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- optionally substituted
- needed
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 136
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 208000017520 skin disease Diseases 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- -1 cyano, nitro, amino Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 208000012641 Pigmentation disease Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 6
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102100036816 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Human genes 0.000 claims description 5
- 101000851788 Homo sapiens Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 claims description 5
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims description 5
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims description 5
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 150000003672 ureas Chemical class 0.000 claims description 5
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 4
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- YQCIWBXEVYWRCW-UHFFFAOYSA-N methane;sulfane Chemical compound C.S YQCIWBXEVYWRCW-UHFFFAOYSA-N 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 150000003871 sulfonates Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 150000003585 thioureas Chemical class 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000219094 Vitaceae Species 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 125000006570 (C5-C6) heteroaryl group Chemical class 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437400P | 2016-12-21 | 2016-12-21 | |
| US62/437,400 | 2016-12-21 | ||
| US201762485563P | 2017-04-14 | 2017-04-14 | |
| US62/485,563 | 2017-04-14 | ||
| US201762538203P | 2017-07-28 | 2017-07-28 | |
| US62/538,203 | 2017-07-28 | ||
| PCT/US2017/067353 WO2018118947A1 (en) | 2016-12-21 | 2017-12-19 | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504711A JP2020504711A (ja) | 2020-02-13 |
| JP2020504711A5 true JP2020504711A5 (enExample) | 2021-02-04 |
Family
ID=60991575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526486A Pending JP2020504711A (ja) | 2016-12-21 | 2017-12-19 | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10040804B2 (enExample) |
| EP (1) | EP3559005A1 (enExample) |
| JP (1) | JP2020504711A (enExample) |
| KR (1) | KR20190093205A (enExample) |
| CN (1) | CN110099907A (enExample) |
| AU (1) | AU2017382176A1 (enExample) |
| CA (1) | CA3043938A1 (enExample) |
| IL (1) | IL267323A (enExample) |
| MX (1) | MX387646B (enExample) |
| RU (1) | RU2771166C2 (enExample) |
| TW (2) | TWI756957B (enExample) |
| WO (1) | WO2018118947A1 (enExample) |
| ZA (1) | ZA201903479B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| KR20190093205A (ko) | 2016-12-21 | 2019-08-08 | 바이오테릭스, 인코포레이티드 | 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
| EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| US10584133B2 (en) * | 2018-03-30 | 2020-03-10 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| CN112601751B (zh) * | 2018-06-13 | 2024-04-02 | 拜欧斯瑞克斯公司 | 稠合噻吩化合物 |
| EP3841098A4 (en) | 2018-08-22 | 2022-05-04 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| WO2020160192A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| FR3092581A1 (fr) * | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
| EA202192738A1 (ru) | 2019-04-12 | 2022-03-17 | С4 Терапьютикс, Инк. | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
| AU2020283744A1 (en) * | 2019-05-24 | 2021-12-09 | Biotheryx, Inc. | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
| KR20220103753A (ko) | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| MX2022007659A (es) | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| TWI877297B (zh) | 2020-01-29 | 2025-03-21 | 美商福宏治療公司 | 化合物及其用途 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN115697989B (zh) | 2020-02-26 | 2025-03-18 | 上海睿跃生物科技有限公司 | 原肌球蛋白受体激酶(trk)降解化合物和使用方法 |
| CN115279370B (zh) | 2020-03-05 | 2025-01-10 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| EP4225749A4 (en) * | 2020-10-07 | 2025-05-14 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| JP2024500377A (ja) | 2020-12-14 | 2024-01-09 | バイオセリックス， インコーポレイテッド | Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| AU2022253242A1 (en) | 2021-04-06 | 2023-11-23 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
| CN117715904A (zh) | 2021-05-07 | 2024-03-15 | 凯麦拉医疗公司 | Cdk2降解剂和其用途 |
| EP4351583A4 (en) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | THERAPEUTICS TO DEGRADE MUTANT BRAF |
| WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| KR20250021314A (ko) | 2022-06-06 | 2025-02-12 | 씨4 테라퓨틱스, 인코포레이티드 | 비시클릭-치환된 글루타르이미드 세레블론 결합제 |
| AU2023338217A1 (en) * | 2022-09-09 | 2025-04-03 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| TW202523291A (zh) | 2023-11-02 | 2025-06-16 | 美商金橘生物科技公司 | 降解劑及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585377A (en) | 1990-04-09 | 1996-12-17 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| DE4023048A1 (de) | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| DE69320329T2 (de) | 1992-02-21 | 1998-12-24 | Alcon Laboratories, Inc., Fort Worth, Tex. | Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker |
| US5420923A (en) | 1993-02-16 | 1995-05-30 | Scientific-Atlanta, Inc. | Addressed messaging in a cable television system |
| US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO1995033746A1 (en) | 1994-06-08 | 1995-12-14 | E.I. Du Pont De Nemours And Company | Cyclic sulfonamide herbicides |
| AU3619795A (en) | 1994-10-11 | 1996-05-02 | Takeda Chemical Industries Ltd. | Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors |
| SK284371B6 (sk) | 1996-02-26 | 2005-02-04 | Advanced Research And Technology Institute | Použitie oftalmologickej kompozície obsahujúcej účinné množstvo lokálneho inhibítora anhydrázy kyseliny uhličitej na prípravu liečiva |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| JPH10264532A (ja) | 1997-03-24 | 1998-10-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| US6906245B1 (en) | 1998-04-30 | 2005-06-14 | Sumitomo Chemical Company, Limited | Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants |
| AU753020B2 (en) | 1998-04-30 | 2002-10-03 | Sumitomo Chemical Company, Limited | Method for giving resistance to weed control compounds to plants |
| JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| JP4821038B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| JP4821036B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| JP2004018434A (ja) | 2002-06-14 | 2004-01-22 | Mitsui Chemicals Inc | 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子 |
| US7247736B2 (en) | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
| NZ541382A (en) | 2002-12-23 | 2009-04-30 | 4Sc Ag | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| US8946444B2 (en) | 2004-11-23 | 2015-02-03 | Ptc Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ES2528316T3 (es) | 2006-09-01 | 2015-02-06 | Senhwa Biosciences, Inc. | Moduladores de la serina-treonina proteína quinasa y de PARP |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| JP2008273924A (ja) | 2007-03-30 | 2008-11-13 | Meiji Seika Kaisha Ltd | ２位チエニルカルバペネム誘導体 |
| KR101128943B1 (ko) | 2007-04-13 | 2012-03-27 | 주식회사 엘지화학 | 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자 |
| CN102245600A (zh) | 2008-10-08 | 2011-11-16 | 百时美施贵宝公司 | 吡咯烷酮黑色素浓集激素受体-1拮抗剂 |
| CA2742910A1 (en) | 2008-11-07 | 2010-05-14 | 4Sc Ag | Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease |
| JP5651681B2 (ja) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法 |
| CA2809662C (en) | 2010-09-01 | 2019-04-16 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
| US20120085992A1 (en) | 2010-09-30 | 2012-04-12 | The Regents Of The University Of California | Furan Conjugated Polymers Useful for Photovoltaic Applications |
| WO2012082893A2 (en) | 2010-12-15 | 2012-06-21 | Plextronics, Inc. | Fluoro monomers, oligomers, and polymers for inks and organic electronic devices |
| KR20140040716A (ko) | 2011-04-15 | 2014-04-03 | 조지아 테크 리서치 코포레이션 | 유기 반도체로서의 나프탈렌-디이미드-헤테로사이클-나프탈렌 디이미드 올리고머 및 그로부터의 트랜지스터 |
| ITMI20110881A1 (it) | 2011-05-18 | 2012-11-19 | E T C Srl | Materiale semiconduttore organico |
| WO2013052153A1 (en) | 2011-10-05 | 2013-04-11 | Georgia Tech Research Corporation | Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices |
| JP2014047196A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子 |
| JP2014047192A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子 |
| CN103664916B (zh) | 2012-09-12 | 2016-08-24 | 中国科学院化学研究所 | 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用 |
| ITMI20121691A1 (it) | 2012-10-09 | 2014-04-10 | E T C Srl | Materiale semiconduttore organico |
| ITMI20121939A1 (it) | 2012-11-15 | 2014-05-16 | E T C Srl | Materiale organico semiconduttore |
| ITMI20121952A1 (it) | 2012-11-16 | 2014-05-17 | E T C Srl | Materiale semiconduttore organico |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| JP2014185147A (ja) | 2013-02-22 | 2014-10-02 | Mitsubishi Chemicals Corp | イミド縮合環化合物及びイミド縮合環化合物の製造方法 |
| JP6248400B2 (ja) | 2013-03-15 | 2017-12-20 | 株式会社リコー | 感光体及び画像形成装置 |
| JP2015013989A (ja) | 2013-06-05 | 2015-01-22 | 三菱化学株式会社 | コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール |
| WO2014204082A1 (ko) | 2013-06-20 | 2014-12-24 | 경상대학교산학협력단 | 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지 |
| KR101595919B1 (ko) | 2013-08-30 | 2016-02-29 | 한국과학기술연구원 | 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지 |
| US9809594B2 (en) | 2013-09-10 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Non-fullerene electron acceptors for organic photovoltaic devices |
| KR101732220B1 (ko) | 2014-03-31 | 2017-05-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 태양 전지 |
| CN105294536B (zh) | 2014-06-30 | 2018-06-29 | 中国科学院上海有机化学研究所 | 一种制备3-亚氨基异吲哚啉酮类化合物的方法 |
| JP7120763B2 (ja) * | 2014-08-22 | 2022-08-17 | セルジーン コーポレイション | 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法 |
| CN104230953B (zh) | 2014-08-25 | 2016-08-17 | 中国科学院上海有机化学研究所 | 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物 |
| WO2016061751A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| CN105693745B (zh) | 2014-11-27 | 2019-07-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 有机π-共轭化合物、其制备方法及应用 |
| CA2986141C (en) | 2015-05-22 | 2020-07-28 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| KR20190093205A (ko) | 2016-12-21 | 2019-08-08 | 바이오테릭스, 인코포레이티드 | 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도 |
-
2017
- 2017-12-19 KR KR1020197018882A patent/KR20190093205A/ko not_active Ceased
- 2017-12-19 JP JP2019526486A patent/JP2020504711A/ja active Pending
- 2017-12-19 RU RU2019115392A patent/RU2771166C2/ru active
- 2017-12-19 MX MX2019007434A patent/MX387646B/es unknown
- 2017-12-19 CA CA3043938A patent/CA3043938A1/en not_active Abandoned
- 2017-12-19 EP EP17829823.8A patent/EP3559005A1/en not_active Withdrawn
- 2017-12-19 WO PCT/US2017/067353 patent/WO2018118947A1/en not_active Ceased
- 2017-12-19 AU AU2017382176A patent/AU2017382176A1/en not_active Abandoned
- 2017-12-19 US US15/847,628 patent/US10040804B2/en active Active
- 2017-12-19 CN CN201780079826.3A patent/CN110099907A/zh active Pending
- 2017-12-21 TW TW109142439A patent/TWI756957B/zh not_active IP Right Cessation
- 2017-12-21 TW TW106145115A patent/TW201835089A/zh unknown
-
2018
- 2018-06-18 US US16/011,090 patent/US10336771B2/en active Active
-
2019
- 2019-05-30 ZA ZA2019/03479A patent/ZA201903479B/en unknown
- 2019-06-13 IL IL267323A patent/IL267323A/en unknown
- 2019-06-28 US US16/457,409 patent/US10889593B2/en active Active
-
2021
- 2021-01-11 US US17/146,479 patent/US11345714B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504711A5 (enExample) | ||
| DE69309094T2 (de) | Hemmung der TNF - Bildung | |
| AU754562B2 (en) | Benzimidazole derivatives as modulators of IgE | |
| RU2019115392A (ru) | Производные тиенопиррола для применения для нацеливания на белки, композиции с указанными производными, способы и применения | |
| RU2593231C2 (ru) | Способы лечения с использованием селективных ингибиторов bcl-2 | |
| AU2012352149B2 (en) | Autoimmune disorder treatment using RXR agonists | |
| TR200100300T2 (tr) | Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri | |
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| RU98105512A (ru) | Применение производных пиримидина для профилактики рака отдельно или в комбинации с другими терапевтическими мероприятиями | |
| WO2020047035A1 (en) | Methods of treating cancer with small molecule pd-l1 inhibitors | |
| JP2006501201A5 (enExample) | ||
| ES2354366T3 (es) | Medicamento para la hiperlipemia. | |
| CN111617078B (zh) | 用于疾病治疗和/或预防的药物组合物、方法及其用途 | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| WO2023059596A1 (en) | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | |
| CN102105144A (zh) | 鞘氨醇1磷酸酯受体调节剂以及它们用于治疗肌肉炎症的用途 | |
| RU2017133660A (ru) | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций | |
| JP2020504122A5 (enExample) | ||
| WO2021194991A1 (en) | Use of losmapimod for treatment of covid-19 | |
| RU2014120411A (ru) | Схема приема модулятора или агониста рецептора s1p | |
| TNSN05080A1 (en) | NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published) | |
| TWI856955B (zh) | 治療過度增生性皮膚病的組合物及方法 | |
| WO2017059434A1 (en) | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of cancer | |
| RU2006138864A (ru) | Ингибиторы митотического кинезина | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 |